ONO-7269

ONO-7269 is an investigational anticoagulant being developed by Ono Pharmaceutical. It is a small molecule inhibitor designed for continuous intravenous infusion. Clinical evaluation has focused on its safety, pharmacokinetics, and pharmacodynamics in healthy subjects, elderly individuals, and patients with varying degrees of renal impairment. A key pharmacodynamic marker used in its development is the effect on activated partial thromboplastin time (APTT), which is a standard measure of the intrinsic and common pathways of coagulation. The drug is intended for use in clinical settings requiring precise, parenteral control of anticoagulation.